• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] >Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy
【24h】

Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy

机译：Sarcopenia是患有Folfirinox化疗的晚期胰腺癌患者的可靠预后因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/objectives: FOLFIRINOX is the reliable treatments for pancreatic cancer, but it has a relatively high toxicity and the selection of suitable patients for this regimen remains challenge. On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer. The aim of this study was to investigate the effect of sarcopenia on overall survival (OS) and time to treatment failure (TTF) in patients with pancreatic cancer who received FOLFIRINOX.
机译：背景/目标：Folfirinox是对胰腺癌可靠的治疗方法，但它具有相对较高的毒性，并且对这种方案的合适患者的选择仍然是挑战。 另一方面，Sarcopenia是胰腺癌的重要预后因素之一。 本研究的目的是探讨SARCOPENIA对接受FOLFIRINOX的胰腺癌患者的整体存活（OS）和治疗失败（TTF）的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号